DOH: Clinical trials on possible COVID-19 vaccine a ‘whole of gov’t’ approach | Inquirer News

DOH: Clinical trials on possible COVID-19 vaccine a ‘whole of gov’t’ approach

By: - Reporter / @KHallareINQ
/ 02:08 PM October 10, 2020

3 int'l COVID-19 vaccine makers gunning for Phase 3 clinical trials in PH

FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter

MANILA, Philippines — The Department of Health (DOH) on Saturday said the process of clinical trials on a possible coronavirus disease (COVID-19) vaccine has a “whole of government” approach, and has a steering committee consisting of the agency, the Food and Drug Administration (FDA) and Department of Science and Technology (DOST).

This comes after Senator Francis Tolentino called out the three government agencies for its “confusing” set up on the vaccine trials in the country.

Article continues after this advertisement

During the Laging Handa online press briefing, DOH Undersecretary and spokesperson Maria Rosario Vergeire said that there is an “institutional structure” observed for the trials.

FEATURED STORIES

“Mayroon ho tayong institutional structure. Ito po yung steering committee on clinical trials kung saan po FDA, DOST and DOH are all working together,” she said.

Article continues after this advertisement

(We have an institutional structure. This is the steering committee on clinical trials where the FDA, DOST and DOH are working together.)

Article continues after this advertisement

“Nagu-umpisa po ‘yan sa Department of Science and Technology kung saan nagtalaga sila ng vaccines experts panel. So lahat po ng magki-clinical trials ay dadaan po sa panel na ito at additional safeguards po ‘yan ng ating gobyerno  para masigurong ligtas at tsaka effective talaga ang  bakuna na ibibigay natin sa ating mga kababayan,” she added.

Article continues after this advertisement

(This starts with the Department of Science and Technology where we have a panel of vaccine experts. So everything that will go through clinical trials will go through this panel, and this is also an additional safeguard of the government to make sure that the vaccines to be given are safe and effective.)

After getting a positive response from the experts’ panel, Vergeire said the next process for the vaccine trial will be to undergo an FDA regulatory process. And if the vaccine gets a positive recommendation and is approved, then the DOH will be the one to implement it.

Article continues after this advertisement

“So this is really a process, lahat po kami nagta-trabaho, sama-sama. This is whole of government and we have a structure for that to oversee that this process will be proper na gagawin para masiguro ang kaligtasan ng ating mga kababayan,” Vergeire said.

(So this is really a process, we are working together. This is whole of government and we have a structure for that to oversee that this process will be proper and to make sure that the people are safe.)

As of Oct. 9, the Philippines’ COVID-19 caseload is at 334,770, with 275,307 recoveries and 6,152 deaths.

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19, nCoV update

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.